PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala

PCI Pharma Services received an investment co-led by Bain Capital and Kohlberg, with significant reinvestment from Mubadala and continued minority participation by Partners Group. The July 2025 transaction supported its drug-development, manufacturing and packaging operations. Financial terms were undisclosed, and individual investors’ ownership percentages were not stated.